NCT05001009 2024-12-27LSTDIVA Office of Research and DevelopmentPhase NA Enrolling by invitation72 enrolled
NCT02921828 2022-07-05A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCelgeneCompleted1,149 enrolled